Journal of the Neurological Sciences
Volume 205, Issue 1 , Pages 5-8 , 15 December 2002

Pro-inflammatory cytokines and motor neuron dysfunction: Is there a connection in post-polio syndrome?

Received 6 August 2002

References 

  1. Dalakas MC. The post-polio syndrome as an evolved clinical entity: definition and clinical description. Ann. N.Y. Acad. Sci. 1995;753:68–80
  2. Halstead LS. Post-polio syndrome. Sci. Am. 1998;278:42–47
  3. Dalakas MC, Hallett M. The post-polio syndrome. In:  Plum F editors. Advances in contemporary neurology. Philadelphia: F.A. Davis; 1988;p. 51–94
  4. Dalakas MC, Elder G, Hallett M, et al.  A long-term follow-up study of patients with postpoliomyelitis neuromuscular symptoms. N. Engl. J. Med. 1986;314:959–963
  5. Dalakas MC. Pathogenetic mechanisms of postpolio syndrome: morphological, electrophysiological, virological and immunopathological correlations. Ann. N.Y. Acad. Sci. 1995;753:167–185
  6. Weichers DO, Hubbell SL. Late changes of the motor unit after acute poliomyelitis. Muscle Nerve. 1981;4:524–528
  7. Cashman NR, Maselli R, Wollman RL, Roos R, Simon R, Antel JP. Late denervation in patients with antecedent paralytic poliomyelitis. N. Engl. J. Med. 1987;317:7–12
  8. Ravits J, Hallett M, Baker M, Nilsson J, Dalakas M. Clinical and electromyographic studies of post-poliomyelitis muscular atrophy. Muscle Nerve. 1990;13:667–674
  9. Dalakas M, Illa I. The post-polio syndrome: concepts in pathogenesis clinical diagnosis, pathogenesis and etiology. Adv. Neurol. 1991;56:495–511
  10. Trojan DA, Collet J-P, Shapiro S, et al.  A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome. Neurology. 1999;53:1225–1233
  11. Dalakas MC. Why drugs fail in post polio syndrome: lessons from another clinical trial. [Editorial] Neurology. 1999;53:1166–1167
  12. Bodian D. An electron-microscopic study of the monkey spinal cord. Cytologic effects of poliovirus infection. Bull. Johns Hopkins Hosp. 1964;114:21–119
  13. Gonzalez H, Khademi M, Andersson M, Wallström Borg K, Olsson T. Prior poliomyelitis-evidence of cytokine production in the central nervous system. J Neurol Sci. 2002;205:9–13
  14. Dinsmore S, Dalakas MC. Are there immunopathologic changes in patients with post-polio syndrome?. In:  Halstead L,  Grimby G editor. Post-polio syndrome. Philadelphia, PA: Hanley & Belfus Medical Publishers; 1994;p. 1–14
  15. Illa I, Leon-Monzon ME, Agboatwalla M, Dure-Samin A, Dalakas MC. Role of the muscle in the acute poliomyelitis infection. Ann. N.Y. Acad. Sci. 1995;753:58–67
  16. Dalakas MC. Morphological changes in the muscles of patients with post-poliomyelitis neuromuscular symptoms. Neurology. 1988;38:99–104
  17. Pezeshkpour GH, Dalakas MC. Long-term changes in the spinal cord of patients with old poliomyelitis: signs of continuous disease activity. Arch. Neurol. 1988;45:505–508
  18. Sharief MK, Hentges R, Ciardi M. Intrathecal immune response in patients with the post-polio syndrome. N. Engl. J. Med. 1991;325:749–755
  19. Miller DC. Post-polio syndrome spinal cord pathology. Case report with immunopathology. Ann. N.Y. Acad. Sci. 1995;753:186–193
  20. Dalakas MC. New neuromuscular symptoms after polio (the post-polio syndrome): clinical studies and pathogenetic mechanisms. In:  Halstead LS,  Wiechers DO editor. Late effects of poliomyelitis. March of dimes. vol. 23:1987;p. 241–264
  21. Ginsberg AG, Gale MJ, Rose LM. T cell alteration in late postpoliomyelitis. Arch. Neurol. 1989;46:497–501
  22. Illa I, Leon-Monzon ME, Agboatwalla M, Ilyas A, Latov N, Dalakas MC. Antiganglioside antibodies in patients with acute polio and post-polio syndrome. Ann. N.Y. Acad. Sci. 1995;753:374–377
  23. Bodian D. Motor neuron disease and recovery in experimental poliomyelitis. In:  Halstead LS,  Wiechers DO editor. Late effects of poliomyelitis. March of dimes. vol. 23:1987;p. 45–55
  24. Calvez I, Pelletier I, Borzakian S, Colbere-Garapin F. Identification of a region of the poliovirus genome involved in persistent infection of Hap-cells. J. Virol. 1993;67:4432–4435
  25. Colbere-Garapin F, Christodoulou C, Crainic R, Pelletier I. Persistent poliovirus infection of human neuroblastoma cells. Proc. Natl. Acad. Sci. U. S. A. 1989;86:7590–7594
  26. Destombes J, Coudert T, Thiesson D, Girard S, Wilt JG, Blondel B. Persistent poliovirus infection in mouse motorneurons. J. Virol. 1997;71:1621–1628
  27. Pelletier I, Duncan G, Pavio N, Colbere-Garapin F. Molecular mechanisms of poliovirus persistence: key role of capsid determinants during the establishment phase. Cell. Mol. Life Sci. 1998;54:1385–1402
  28. Leon-Monzon ME, Dalakas MC. Detection of poliovirus antibodies and poliovirus genome in patients with the post-polio syndrome. Ann. N.Y. Acad. Sci. 1995;753:208–218
  29. Muir P, Nicholson F, Sharief MK, Thompson EJ, Cairnes NJ, Lantos P, et al.  Evidence for persistent enterovirus infection of the central nervous system in patients with previous paralytic poliomyelitis. Ann. N.Y. Acad. Sci. 1995;753:219–232
  30. Julien J, Lepare-Goffart I, Lina B, et al.  Postpolio syndrome: poliovirus persistence is involved in the pathogenesis. J. Neurol. 1999;246:276–472
  31. Mullington JM, Hinze-Selch D, Pollmacher T. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Ann. N.Y. Acad. Sci. 2001;933:201–210
  32. Patarca R. Cytokines and chronic fatigue syndrome. Ann. N.Y. Acad. Sci. 2001;933:185–200
  33. Quan N, Herkenham M. Connecting cytokines and brain: a review of current issues. Histol. Histopathol. 2002;17:273–288
  34. Raine CS. Multiple Sclerosis: immune system molecule expression in the central nervous system. J. Neuropathol. Exp. Neurol. 1994;53:328–337
  35. Semino-Mora C, Dalakas MC. Rimmed vacuoles with B-Amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (post-poliomyelitis muscular atrophy): similarities with inclusion body myositis. Hum. Pathol. 1998;29:1128–1133
  36. Dinsmore ST, Dambrosia JM, Dalakas MC. A double blind, placebo-controlled trial of high-dose prednisone for the treatment of post-poliomyelitis syndrome. Ann. N.Y. Acad. Sci. 1995;753:303–313
  37. Dalakas MC, Aksamit AJ, Madden DL, Sever JL. Recombinant I2 interferon in a pilot trial of patients with amyotrophic lateral sclerosis. Arch. Neurol. 1986;43:933–935

PII: S0022-510X(02)00314-3

Journal of the Neurological Sciences
Volume 205, Issue 1 , Pages 5-8 , 15 December 2002

Article Tools